| abstract |
The invention relates to benzimidazole compounds capable of suppressing gastric acid secretion, resisting helicobacter pylori and exerting targeted inhibition of activity gastric cancer cells of the formula on the right. Structurally, the compounds have two benzimidazole active functional groups which can be combined with two cysteine residues in a H<+>, K<+>-adenosine triphosphatase (ATP) monomer or two cysteine residues in an oligomer after being activated by the gastric acid in vivo to inhibit the activity of the H<+>, K<+>-ATP. The compounds can selectively inhibit the activity of Hp. A, B, L, R1 and n are defined in the claim 1. |